Your browser doesn't support javascript.
loading
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay
Markus H Kainulainen; Eric Bergeron; Payel Chatterjee; Asheley P Chapman; Joo Lee; Asiya Chida; Xiaoling Tang; Rebekah E Wharton; Kristina B Mercer; Marla Petway; Harley M Jenks; Timothy D Flietstra; Amy J Schuh; Panayampalli S Satheshkumar; Jasmine M Chaitram; S Michele Owen; M G Finn; Jason M Goldstein; Joel M Montgomery; Christina F Spiropoulou.
Afiliação
  • Markus H Kainulainen; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Eric Bergeron; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Payel Chatterjee; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Asheley P Chapman; School of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Joo Lee; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Asiya Chida; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Xiaoling Tang; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Rebekah E Wharton; Emergency Response Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Kristina B Mercer; Newborn Screening & Molecular Biology Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Marla Petway; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Harley M Jenks; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Timothy D Flietstra; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Amy J Schuh; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Panayampalli S Satheshkumar; Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Jasmine M Chaitram; Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • S Michele Owen; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • M G Finn; School of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Jason M Goldstein; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Joel M Montgomery; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Christina F Spiropoulou; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
Preprint em Inglês | medRxiv | ID: ppmedrxiv-20195446
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA.
Licença
cc0
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Pesquisa qualitativa Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Pesquisa qualitativa Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint